Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B. · 2017
Read Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. by Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5730103.txt.
Introduction
Ponte-Sucre and co-authors review drug resistance in leishmaniasis, a disease spread by sand flies. Treatment failure is rising in many regions, they report. Old drugs based on antimony have lost ground in parts of India. Weak immunity, not least from HIV, adds to the problem.
The review sets out what resistance means for this disease and how it spreads. It covers the workings of resistance to antimonials, amphotericin B, and miltefosine. Drug pairs, now a main hope, can also select for resistant parasites. The authors call for fresh treatment guidance across both Old and New World forms.
Catalog record
| CREATOR | Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge By Alicia Ponte-Sucre, Francisco Gamarro, Jean-Claude Dujardin, Michael P Barrett, Rogelio López-Vélez, Raquel García-Hernández, Andrew W Pountain, Roy Mwenechanya, Barbara Papadopoulou, Louis Maes Published in: PLoS Neglected Tropical Diseases DOI: 10.1371/journal.pntd.0006052 ABSTRACT Abstract Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of “resistance” related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined. INTRODUCTION The leishmaniases are complex diseases of (sub)tropical regions of the world caused by Leishmania spp. (Protozoa, Kinetoplastida, Trypanosomatidae) and spread by sand flies. The World Health Organization (WHO) considers the leishmaniases to be prominent among the global causes of death by infectious diseases [1]. Clinical manifestations produced by Leishmania comprise the visceral (VL) and tegumentary forms. The tegumentary forms of the disease include the cutaneous (CL), diffuse (DCL), and mucocutaneous (MCL) leishmaniases [1], but infections remain asymptomatic in many cases [2, 3]. Leishmania may also appear as an opportunistic parasite in immunosuppressed individuals. Chemotherapy constitutes the main approach to manage the disease although it is generally not applied to asymptomatic subjects. For a number of other neglected tropical diseases, mass drug administration—even without diagnosis—is possible, given the safety of particular drugs used in these circumstances (e.g., praziquantel in schistosomiasis and ivermectin for lymphatic filariasis). The combined problems of parenteral administration and toxicity of anti-leishmanials precludes such programs for leishmaniasis. Furthermore, the selection of resistant parasites carrying genetic mutations that lessen the parasite's response to drugs may emerge upon mass drug administration. Leishmania has an intricate life cycle, and one of the developmental forms, the amastigote, dwells within immunological cells of the mammalian host, which adds to the challenge of accessing the parasites with specific drugs. Nevertheless, the aim of chemotherapy is to kill intracellular parasites; therefore, chemotherapy remains the best means available to cure the disease [4]. Antimonials (sodium stibogluconate [SSG]) are the primary drugs employed against leishmaniasis. They have been in use since the 1920s. These toxic compounds have a narrow therapeutic window, and their use has been largely superseded in the ISC, where resistance has become widespread. However, they are still in use in other regions of the world, including Latin America and East Africa [5,6]. MIL has replaced SSG in the ISC in the context of the kala-azar elimination program, but efficacy of this drug as well had already dropped within a decade of its introduction [7, 8]. Initially, this decrease in MIL efficacy could not be related to increasing parasite resistance to the drug [8], although recently a few resistant clinical isolates have been described, first in France in an HIV-coinfected patient and later in two Indian patients [9, 10, 11]. AmB is highly efficacious but relatively toxic when injected in its free deoxycholate form. Administration in a liposomal formulation ameliorates the toxicity risk, although the high cost of this formulation has left its range of use restricted; this is the case even though it is provided free of charge to WHO for use in strategically important areas by its manufacturers (Gilead Sciences; with up to 350,000 vials over the next five years). Unfortunately, a risk of resistance is becoming apparent for AmB as well (discussed below). Paromomycin has a relatively restricted range of targeting Leishmania species, and the situation regarding resistance in the field is unclear, although laboratory-derived resistant isolates have been created [12–15]. Even combination therapies are not immune from selection of resistance, which poses potential challenges to the WHO’s proposed next generation of combination therapies in the treatment of leishmaniasis. It is critical to consider that TF and drug resistance (DR) are not necessarily synonymous. TF goes far beyond DR, with numerous factors in the host (such as immunity or nutritional status), the parasite (e.g., whether or not the parasite resides in tissues not accessible to drugs), and the environment (e.g., global warming contributing to the expansion of the disease to new geographical areas) influencing treatment outcomes. Notwithstanding, DR is a fundamental determinant of treatment outcome, and understanding the mechanisms whereby parasites become resistant to drugs is essential. In this Review, we discuss the phenomenon of DR associated with SSG, AmB, and MIL and outline the molecular mechanisms associated with the selection of resistance in combination therapies, as well as the possible consequences of emergent resistance on the use of these drugs in the field. TF BEYOND DR A growing number of questions apply to treatment options for leishmaniasis. For example, why do patients with the same clinical form of the disease, living in the same areas, infected by the same species of Leishmania, and treated with the same drug regimen differ in their response to treatment? What are the causes of TF? To help address these questions from the parasitological point of view, two key requirements are (1) to find a sensitive and practical technique to determine the persistence, or the elimination, of viable parasites in clinical samples after treatment and (2) to define and standardize tests of sensitivity and resistance in vitro. Numerous features are known to impact the final therapeutic outcome (see Fig 1). [Figure: Summary of the factors that influence TF and DR in Leishmania.ABC, ATP-binding cassette; AQP, aquaporin; DR, drug resistance; LRV, Leishmania RNA virus; TF, treatment failure.] Host factors play a role. For example, because an effective immune response is required to support anti-leishmanial drugs, patients with immunodeficiency can be particularly hard to cure [16]. Less extreme natural variation in host immunological response can also influence the ability of a drug to work. To date, little has been done to assess the effect of individual variation in pharmacokinetics or other drug-related responses in the host. Differences between individuals are normal for most drugs, and stratified responses are clearly observed for the leishmaniases. Examples include when comparing children versus adults or males versus females [17, 18, 19] and in instances in which a patient who may have failed initial treatment responds to a second cycle of a drug given at a higher dose [20]. It is also clear that parasite factors other than explicitly acquired resistance can also play a role. These factors comprise the inherent virulence of the infecting isolate of Leishmania [21] and—in some instances—parasite infection by RNA viruses [22, 23], whose occurrence can stimulate a different kind of immunological response in the host [24]. TF may occur with susceptible strains in immunocompromised patients [25, 26], and ill-defined regional differences in response are known [27, 28]. Finally, TF may occur in similar clinical cases that respond